BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
33510545
Number of visits today
1297
Number of downloads
16697273
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Giglhuber K, Berthele A. Eculizumab in the treatment of neuromyelitis optica spectrum disorder. Immunotherapy 2020;12:1053-66. [PMID: 32772617 DOI: 10.2217/imt-2020-0163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Kim W, Kim HJ. An update on biologic treatments for neuromyelitis optica spectrum disorder. Expert Rev Clin Immunol 2023;19:111-21. [PMID: 36414430 DOI: 10.1080/1744666X.2023.2151441] [Reference Citation Analysis]
2 Ghosh K, Ghosh K. Monoclonal antibodies used for the management of haematological disorders. Expert Rev Hematol 2022. [PMID: 35504000 DOI: 10.1080/17474086.2022.2073213] [Reference Citation Analysis]
3 Luitel P, Ghimire A, Upadhyay D, Ojha R. Efficacy of monoclonal antibodies in neuromyelitis optica: An updated systematic review with meta‐analysis. Clinical & Exp Neuroim 2022. [DOI: 10.1111/cen3.12695] [Reference Citation Analysis]
4 Ghosh K, Ghosh K. Monoclonal antibodies used for management of hematological disorders. JHAS 2021;1:12-21. [DOI: 10.25259/jhas_2_2021] [Reference Citation Analysis]
5 Waliszewska-Prosół M, Chojdak-Łukasiewicz J, Budrewicz S, Pokryszko-Dragan A. Neuromyelitis Optica Spectrum Disorder Treatment-Current and Future Prospects. Int J Mol Sci 2021;22:2801. [PMID: 33802046 DOI: 10.3390/ijms22062801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345